Ceribell, the maker of a portable, brain-reading headset for emergency seizure care, aims to go public on the Nasdaq through ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

A year after the failure of an idiopathic pulmonary fibrosis candidate sent Galecto on a search for salvation, the ...

A startup that aims to deliver a blood test to identify a biomarker linked with a specific subtype of autism—and then ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus ...

The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. | The Nobel Assembly at the Karolinska Institute has taken a liking to RNA. The committee has awarded two American biologists ...

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

Psyence Biomedical has walked away from its planned acquisition of fellow Canadian psilocybin-based biotech Clairvoyant ...